Lichenoid Dermatologic Toxicity from Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features

American Journal of Dermatopathology

Volumn 39, Issue 2, 2017, Pages 121-129

  Tetzlaff, Michael T ^a   Nagarajan, Priyadharsini ^a   Chon, Susan ^b   Huen, Auris ^b   Diab, Adi ^a   Omar, Pacha ^b   Aung, Phyu P ^a   Torres Cabala, Carlos A ^a,b   Mays, Steven R ^b   Prieto, Victor G ^a,b   Curry, Jonathan L ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Health Science Center at Houston   (United States)

Author keywords

anti PD 1 PD L1 antibodies; lichenoid dermatologic toxicities; nivolumab; pembrolizumab

Indexed keywords

AMLODIPINE; ATORVASTATIN; BEVACIZUMAB; CARBOPLATIN; CLOBETASOL; DIPHENHYDRAMINE; ENOXAPARIN; FENOFIBRATE; FLUOCINONIDE; HYDROXYZINE; INSULIN GLULISINE; IPILIMUMAB; LEVOTHYROXINE; LISINOPRIL; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PREDNISONE; TRIAMCINOLONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ACANTHOSIS; ADENOCARCINOMA; ADULT; AGED; ARTICLE; BRAIN SPONGIOSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DYSKERATOSIS; FEMALE; HUMAN; HYPERKERATOSIS; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; LEUKEMIC INFILTRATION; LICHENOID; LUNG EMBOLISM; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PARAKERATOSIS; PRIORITY JOURNAL; PUSTULAR PSORIASIS; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; SKIN TOXICITY; ULCER; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG ERUPTIONS; LICHENOID ERUPTION; NEOPLASMS; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; LICHENOID ERUPTIONS; MALE; MIDDLE AGED; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85011263105     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0000000000000688     Document Type: Article

References (21)

1. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimu-mab in advanced melanoma. N Engl J Med. 2015;372:2521-2532.
2. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004-2012.
3. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366: 2443-2454.
4. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375-384.
5. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol. 2015;11:2471-2484.
6. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014;372:320-330.
7. Totonchy MB, Ezaldein HH, Ko CJ, et al. Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Derma-tol. 2106;152:590-592.
8. Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016 [epub ahead of print].
9. Sibaud V, David I, Lamant L, et al. Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. Melanoma Res. 2015;25: 555-558.
10. Carlos G, Anforth R, Chou S, et al. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015;25:265-268.
11. Weedon D. Chapter 3. In Skin Pathology. 3rd ed. London, United Kingdom: Churchill Livingston; 2010.
12. Asarch A, Gottlieb AB, Lee J, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol. 2009;61:104-111.
13. Bakkour W, Coulson IH. GA101 (a novel anti-CD20 monoclonal antibody)-induced lichenoid eruption. Dermatol Ther. 2012;2:3.
14. Kuten-Shorrer M, Hochberg EP, Woo SB. Lichenoid mucosal reaction to rituximab. Oncologist 2014;19:e12-13.
15. Joseph RW, Cappel M, Goedjen B, et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015;3:18-22.
16. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167-3175.
17. Schaberg KB, Novoa RA, Wakelee HA, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol. 2016;43:339-346.
18. Hwang SJ, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74: 455-461.
19. Minkis K, Garden BC, Wu S, et al. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69:e121-128.
20. Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:1810-1815.
21. Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4:383-389.